4.6 Review

Cannabinoids and Epilepsy

期刊

NEUROTHERAPEUTICS
卷 12, 期 4, 页码 747-768

出版社

SPRINGER
DOI: 10.1007/s13311-015-0375-5

关键词

Epilepsy; seizures; cannabinoids; cannabidiol; THC; cannabis

资金

  1. GW Pharmaceuticals
  2. National Institute of Mental Health [5R37MH071739]
  3. National Institute of Neurological Disorders and Stroke [5R01NS074785, 5R01NS024067]

向作者/读者索取更多资源

Cannabis has been used for centuries to treat seizures. Recent anecdotal reports, accumulating animal model data, and mechanistic insights have raised interest in cannabis-based antiepileptic therapies. In this study, we review current understanding of the endocannabinoid system, characterize the pro- and anticonvulsive effects of cannabinoids [e.g., Delta 9-tetrahydrocannabinol and cannabidiol (CBD)], and highlight scientific evidence from pre-clinical and clinical trials of cannabinoids in epilepsy. These studies suggest that CBD avoids the psychoactive effects of the endocannabinoid system to provide a well-tolerated, promising therapeutic for the treatment of seizures, while whole-plant cannabis can both contribute to and reduce seizures. Finally, we discuss results from a new multicenter, open-label study using CBD in a population with treatment-resistant epilepsy. In all, we seek to evaluate our current understanding of cannabinoids in epilepsy and guide future basic science and clinical studies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据